Could a neck injection stop Post-Surgery heart flutters?

NCT ID NCT06271707

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tests whether a left-sided stellate ganglion block using bupivacaine can lower the rate of atrial fibrillation after esophagectomy, pneumonectomy, or lobectomy. 48 adults aged 18-85 undergoing these surgeries will receive either the nerve block or a saline placebo. The main goal is to see if the block reduces atrial fibrillation in the first week after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bupivacaine

What this could lead to

If it works, this could point toward a simple injection to prevent a common heart rhythm problem after major chest surgery.

What could go wrong

This is a very small pilot study with only 48 people, so results may not be conclusive. The nerve block itself carries rare risks like bleeding or nerve damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGECTOMY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••